Unrestricted Diet for Screening Colonoscopy

NCT ID: NCT05032794

Last Updated: 2022-12-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

553 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-13

Study Completion Date

2022-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Colonoscopy is the technique of choice for the evaluation of the mucosa of the colon. To be able to do the procedure in optimal conditions, it needs to be clean. Therefore, it is necessary to carry out a preparation as safe and tolerable as possible. This preparation generally consists in a low residue diet the days before the colonoscopy and in the intake of a laxative solution. In previous studies, it has been shown that the low residue diet does not play a relevant role as it was considered before. Recent studies demonstrated that reducing the days of low residue diet does not worsen the cleansing and improves the patient experience. The results of this study are required for determining the role of diet restrictive diet in colon cleansing.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bowel Cleansing Colonoscopy Bowel Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

TRIPLE

Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Unrestricted diet

The participant is not instructed to follow any dietary recommendation before colonoscopy. But only the restriction and fasting required for sedation.

Group Type EXPERIMENTAL

Unrestricted diet before colonoscopy

Intervention Type OTHER

Free diet, without restrictions

Bisacodyl 5 MG

Intervention Type DRUG

If the participant is at risk of inadequate bowel cleansing, defined by a score of Dik et al ≥ 2 it will be given Bisacodyl 5 milgrams bid for 3 days.

One day low residue diet

The participant is instructed to follow a low residue diet the day before the colonoscopy.

It will be given a informative document and educated by a nurse.

Group Type ACTIVE_COMPARATOR

1-day low residue diet

Intervention Type OTHER

To follow a diet low in residues / fiber. the day before the colonoscopy.

Bisacodyl 5 MG

Intervention Type DRUG

If the participant is at risk of inadequate bowel cleansing, defined by a score of Dik et al ≥ 2 it will be given Bisacodyl 5 milgrams bid for 3 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Unrestricted diet before colonoscopy

Free diet, without restrictions

Intervention Type OTHER

1-day low residue diet

To follow a diet low in residues / fiber. the day before the colonoscopy.

Intervention Type OTHER

Bisacodyl 5 MG

If the participant is at risk of inadequate bowel cleansing, defined by a score of Dik et al ≥ 2 it will be given Bisacodyl 5 milgrams bid for 3 days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals on the early colorectal cancer detection program who agreed to undergo colonoscopy after positive results on the fecal immunochemical test (FIT)

Exclusion Criteria

* Individuals in which colonoscopy, cleansing solution or bisacodyl are contraindicated
* Subjects that are considered to have a linguistic barrier or to be unable to understand the instructions and / or give informed consent.
Minimum Eligible Age

50 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Parc Taulí Hospital Universitari

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Salvador Machlab

Gastroenterology Consultant

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Salvador Machlab

Role: PRINCIPAL_INVESTIGATOR

Corporació Sanitaria Parc Taulí. Universidad Autónoma de Barcelona.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital de Mataró. Consorci Sanitari del Maresme.

Mataró, Barcelona, Spain

Site Status

Hospital Universitari Parc Taulí

Sabadell, Barcelona, Spain

Site Status

Hospital Universitario de Canarias

San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain

Site Status

Consorci Sanitari de Terrassa

Terrassa, , Spain

Site Status

Hospital Universitary Mutua de Terrassa

Terrassa, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

References

Explore related publications, articles, or registry entries linked to this study.

Machlab S, Martinez-Bauer E, Lopez P, Ruiz-Ramirez P, Gomez B, Gimeno-Garcia AZ, Pujals MDM, Tanco S, Sargatal L, Perez B, Justicia R, Enguita M, Pique N, Valero O, Calvet X, Campo R. Restrictive diets are unnecessary for colonoscopy: Non-inferiority randomized trial. Endosc Int Open. 2024 Mar 7;12(3):E352-E360. doi: 10.1055/a-2256-5356. eCollection 2024 Mar.

Reference Type DERIVED
PMID: 38464979 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021/3009

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.